Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Feb;41(2):331–336. doi: 10.1128/aac.41.2.331

Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.

S P Franzot 1, A Casadevall 1
PMCID: PMC163710  PMID: 9021188

Abstract

Cryptococcus neoformans infections in patients with AIDS are often incurable, despite aggressive antifungal therapy. Combination regimens with additive or synergistic drugs could provide additional options for treating cryptococcal meningitis. We evaluated the efficacy of combination therapies using L-743,872, a pneumocandin antifungal drug, and amphotericin B or fluconazole against 18 strains of C. neoformans, including 11 C. neoformans var. neoformans, 3 C. neoformans var. gattii, and 4 fluconazole-resistant isolates. The combination of subinhibitory concentrations of L-743,872 with amphotericin B significantly enhanced amphotericin B activity against C. neoformans as measured by turbidity (antifungal susceptibility studies using the National Committee of Clinical and Laboratory Standards method), quantitative CFU, and tetrazolium salt reduction assays. Similarly, the addition of subinhibitory concentrations of L-743,872 to fluconazole enhanced fluconazole activity, but the effect was less dramatic than for the pneumocandin-amphotericin B combination. A marked synergism was observed in all combinations of amphotericin B and L-743, 872 (fractional inhibitory concentration index [FIC] of < or = 0.5). Fluconazole-resistant strains showed a susceptibility to amphotericin B and L-743,872 which was comparable to that of susceptible isolates. Combinations of pneumocandin with fluconazole revealed different activities for the various strains, including synergism (FIC < 1.0), additivity (FIC = 1.0), and autonomy (FIC between 1.0 and 2.0). Combination studies with fluconazole and L-743,872 showed additive and autonomous activities against fluconazole-resistant isolates. No antagonistic interactions (FIC < 2.0) were observed for any combination of L-743,872 with either amphotericin B or fluconazole. The results of this study suggest that L-743,872 can enhance the efficacy of fluconazole or amphotericin B in vitro and indicate a potential role for L-743,872 in combination therapy against C. neoformans.

Full Text

The Full Text of this article is available as a PDF (277.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abruzzo G. K., Flattery A. M., Gill C. J., Kong L., Smith J. G., Krupa D., Pikounis V. B., Kropp H., Bartizal K. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1995 May;39(5):1077–1081. doi: 10.1128/aac.39.5.1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartizal K., Scott T., Abruzzo G. K., Gill C. J., Pacholok C., Lynch L., Kropp H. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother. 1995 May;39(5):1070–1076. doi: 10.1128/aac.39.5.1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brandt M. E., Hutwagner L. C., Klug L. A., Baughman W. S., Rimland D., Graviss E. A., Hamill R. J., Thomas C., Pappas P. G., Reingold A. L. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol. 1996 Apr;34(4):912–917. doi: 10.1128/jcm.34.4.912-917.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Currie B. P., Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis. 1994 Dec;19(6):1029–1033. doi: 10.1093/clinids/19.6.1029. [DOI] [PubMed] [Google Scholar]
  5. Franzot S. P., Hamdan J. S. Effect of amphotericin B on the lipids of five different strains of Cryptococcus neoformans. Mycopathologia. 1994 Nov;128(2):85–89. doi: 10.1007/BF01103014. [DOI] [PubMed] [Google Scholar]
  6. Jahn B., Martin E., Stueben A., Bhakdi S. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol. 1995 Mar;33(3):661–667. doi: 10.1128/jcm.33.3.661-667.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kwon-Chung K. J., Polacheck I., Bennett J. E. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982 Mar;15(3):535–537. doi: 10.1128/jcm.15.3.535-537.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Meshulam T., Levitz S. M., Christin L., Diamond R. D. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). J Infect Dis. 1995 Oct;172(4):1153–1156. doi: 10.1093/infdis/172.4.1153. [DOI] [PubMed] [Google Scholar]
  9. Nguyen M. H., Barchiesi F., McGough D. A., Yu V. L., Rinaldi M. G. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother. 1995 Aug;39(8):1691–1695. doi: 10.1128/aac.39.8.1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Spitzer E. D., Spitzer S. G., Freundlich L. F., Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet. 1993 Mar 6;341(8845):595–596. doi: 10.1016/0140-6736(93)90354-j. [DOI] [PubMed] [Google Scholar]
  12. Sugar A. M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Oct;85(4):481–489. doi: 10.1016/s0002-9343(88)80082-2. [DOI] [PubMed] [Google Scholar]
  13. Tellier R., Krajden M., Grigoriew G. A., Campbell I. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother. 1992 Aug;36(8):1619–1625. doi: 10.1128/aac.36.8.1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zuger A., Louie E., Holzman R. S., Simberkoff M. S., Rahal J. J. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986 Feb;104(2):234–240. doi: 10.7326/0003-4819-104-2-234. [DOI] [PubMed] [Google Scholar]
  15. de Lalla F., Pellizzer G., Vaglia A., Manfrin V., Franzetti M., Fabris P., Stecca C. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis. 1995 Feb;20(2):263–266. doi: 10.1093/clinids/20.2.263. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES